Neuraptive Therapeutics, Inc., a Lafayette, Colo.-based and Philadelphia, PA-based biotech startup, raised $11.5m in Series A funding.
The round was led by New Rhein Healthcare Investors LLC.
The company will use the funds to further develop its flagship product, the AxoFuse Nerve Repair System (AxoFuse™), in clinical trials and to expand operations.
Led by David Jackson, CEO and co-founder, Neuraptive was established to develop and commercialize novel nerve repair technologies to improve clinical outcomes for patients and the surgeons who care for them. The company aims to improve clinical outcomes for patients with peripheral nerve injuries with AxoFuse™, a novel therapeutic product for use in conjunction with standard nerve repair surgery. Clinical trials are anticipated to begin in 2019.